Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024Ophthalmology Innovation Summit XIV, November 23, 2024MELBOURNE, ...

A device that delivers a tyrosine kinase inhibitor can improve visual acuity and central subfield thickness in patients with diabetic macular edema, a 16-week phase 2 trial shows. Patients with ...

AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital, dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet ...

Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - ...

High-dose aflibercept, administered every 12 to 16 weeks for 96 weeks, improves visual acuity in several patient subgroups.

RVO biomarkers can be established using an AI that draws out from intravenous fluorescein angiography and baseline characteristics.

Sunir J. Garg, MD, reflects on the recent American Academy of Ophthalmology meeting in Chicago and shares key insights on managing diabetic macular edema (DME). Dr Garg highlights new data showing ...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...

The ELEVATUM study is designed to investigate how faricimab impacts DME in Black Americans. By enrolling, you'll contribute ...

Oculis has multiple late-stage programs and catalysts. Click here to find out why I think OCS stock looks attractive.

Macular edema, a complication of DR, is a slower leakage of fluid into the areas of the eye responsible for sharp vision, usually causing blurred vision. The annual exams can give advance warning of ...